ProCE Banner Activity

APL-2006: Role of Consolidation ATO in Standard-Risk APL

Slideset Download
Conference Coverage
Results from this phase III trial suggest that addition of ATO to frontline chemotherapy may further reduce relapse rates in APL.

Released: December 11, 2015

Expiration: December 09, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Millennium Takeda

Seagen